Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Teva
Julphar
Chubb
Boehringer Ingelheim
Express Scripts
Cantor Fitzgerald
US Department of Justice
Covington

Generated: December 10, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR AGGRENOX

« Back to Dashboard

Clinical Trials for Aggrenox

Trial ID Title Status Sponsor Phase Summary
NCT00067119 Vascular Access Clinical Trials Data Coordinating Center Completed Baystate Medical Center Phase 3 Fistula Study: The objective of the study is to determine whether clopidogrel reduces the early failure rate of native AV fistulae. Graft Study: The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs primary unassisted patency in newly created arteriovenous grafts.
NCT00067119 Vascular Access Clinical Trials Data Coordinating Center Completed Boston University Phase 3 Fistula Study: The objective of the study is to determine whether clopidogrel reduces the early failure rate of native AV fistulae. Graft Study: The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs primary unassisted patency in newly created arteriovenous grafts.
NCT00067119 Vascular Access Clinical Trials Data Coordinating Center Completed CAMC Health System Phase 3 Fistula Study: The objective of the study is to determine whether clopidogrel reduces the early failure rate of native AV fistulae. Graft Study: The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs primary unassisted patency in newly created arteriovenous grafts.
NCT00067119 Vascular Access Clinical Trials Data Coordinating Center Completed Duke University Phase 3 Fistula Study: The objective of the study is to determine whether clopidogrel reduces the early failure rate of native AV fistulae. Graft Study: The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs primary unassisted patency in newly created arteriovenous grafts.
NCT00067119 Vascular Access Clinical Trials Data Coordinating Center Completed Emory University Phase 3 Fistula Study: The objective of the study is to determine whether clopidogrel reduces the early failure rate of native AV fistulae. Graft Study: The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs primary unassisted patency in newly created arteriovenous grafts.
NCT00067119 Vascular Access Clinical Trials Data Coordinating Center Completed Maine Medical Center Phase 3 Fistula Study: The objective of the study is to determine whether clopidogrel reduces the early failure rate of native AV fistulae. Graft Study: The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs primary unassisted patency in newly created arteriovenous grafts.
NCT00067119 Vascular Access Clinical Trials Data Coordinating Center Completed St. Louis University Phase 3 Fistula Study: The objective of the study is to determine whether clopidogrel reduces the early failure rate of native AV fistulae. Graft Study: The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs primary unassisted patency in newly created arteriovenous grafts.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Aggrenox

Condition Name

Condition Name for Aggrenox
Intervention Trials
Healthy 6
Cerebrovascular Accident 3
Stroke 2
Carotid Stenosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Aggrenox
Intervention Trials
Stroke 4
Atherosclerosis 1
Lupus Erythematosus, Systemic 1
Pure Autonomic Failure 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Aggrenox

Trials by Country

Trials by Country for Aggrenox
Location Trials
United States 54
Canada 9
Australia 4
Japan 2
Germany 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Aggrenox
Location Trials
Tennessee 3
Texas 2
North Carolina 2
Missouri 2
Massachusetts 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Aggrenox

Clinical Trial Phase

Clinical Trial Phase for Aggrenox
Clinical Trial Phase Trials
Phase 4 3
Phase 3 3
Phase 1/Phase 2 1
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Aggrenox
Clinical Trial Phase Trials
Completed 12
Recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Aggrenox

Sponsor Name

Sponsor Name for Aggrenox
Sponsor Trials
Boehringer Ingelheim 10
Vanderbilt University Medical Center 2
Maine Medical Center 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Aggrenox
Sponsor Trials
Other 19
Industry 12
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Cipla
Express Scripts
QuintilesIMS
Baxter
Citi
US Army
McKinsey
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.